Instant Access To 100,000+ Essays!

It is all about the lies An ethical analysis on the Martha Stewart Case Gone are the days where CEO’s and executives walk beyond the law. The past two years have been abundant with victories of justice against white collar crimes. Yet these cases should also be seen as a loss for corporate America as it was such a harsh reminder of an often overlooked issue called ethics. Martha Stewart was the latest example of how small unethical decisions could ruin a lifetime of accomplishment. No one knows what was going through her mind the day of her conviction, especially not the author of this paper. The rest of this paper will first elaborate the case and continue to give an evaluation of the ethical compromises made. The case started as a common case of insider trading when Martha Stewart cashed her holdings of ImClone on December 27, 2001. The price per share at the time was 58.43 and she collected a total of $229,500. The insider trading suspicion began when the Food and Drug Administration announced its refusal to review ImClone’s application for its promising cancer drug, Erbitrux. The price of the ImClone’s stock went down to 45.39 per share on December 31st and Stewart gained $51,200 by selling on the 27th.